<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/59EE6C94-CB2C-4AB3-9A0B-EAAF5A6550CD"><gtr:id>59EE6C94-CB2C-4AB3-9A0B-EAAF5A6550CD</gtr:id><gtr:name>The Pirbright Institute</gtr:name><gtr:department>UNLISTED</gtr:department><gtr:address><gtr:line1>Ash Road</gtr:line1><gtr:line2>Pirbright</gtr:line2><gtr:line4>Woking</gtr:line4><gtr:line5>Surrrey</gtr:line5><gtr:postCode>GU24 0NF</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/59EE6C94-CB2C-4AB3-9A0B-EAAF5A6550CD"><gtr:id>59EE6C94-CB2C-4AB3-9A0B-EAAF5A6550CD</gtr:id><gtr:name>The Pirbright Institute</gtr:name><gtr:address><gtr:line1>Ash Road</gtr:line1><gtr:line2>Pirbright</gtr:line2><gtr:line4>Woking</gtr:line4><gtr:line5>Surrrey</gtr:line5><gtr:postCode>GU24 0NF</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/E7D39CBA-2FD7-4E37-BD24-9E7C0C5B1391"><gtr:id>E7D39CBA-2FD7-4E37-BD24-9E7C0C5B1391</gtr:id><gtr:firstName>Simon</gtr:firstName><gtr:surname>Gubbins</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=BBS%2FE%2FI%2F00001609"><gtr:id>14F8BCB7-FFFF-4F39-BD7B-C08D5A1D5F4E</gtr:id><gtr:title>IAH-funded studentship: Field evaluation of the effectiveness of foot and mouth disease vaccines and vaccination programme</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>BBS/E/I/00001609</gtr:grantReference><gtr:abstractText>Although FMD vaccines are widely used, little is done to directly measure the extent to which they protect populations against disease, relying instead on measures of serology as a correlate of protection. It is proposed to apply methods developed for field evaluation of human vaccination programmes to (a) measure patterns of FMD vaccination coverage by age, season, breed, area, etc, and identify important groups of un- and undervaccinated animals; (b) measure the protection against infections and disease afforded by FMD vaccination by age, dose and time since last dose in different epidemiological groups; and (c) evaluate how serology relates to protection against FMD in vaccinated cattle. The work will focus on data collected by national veterinary services and in appropriately designed field investigations. Such studies have provided vital information for major human vaccination programmes (e.g. unexpected variations in vaccine effectiveness, optimal dosing strategies, links between pathogen typing and field protection). We believe that these studies will be equally important for FMD vaccines and will provide evaluation methods that will be of great benefit to veterinary vaccination programmes in general.</gtr:abstractText><gtr:fund><gtr:end>2014-05-23</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name></gtr:funder><gtr:start>2011-05-03</gtr:start><gtr:type>EXPENDITURE_PROJECTED</gtr:type><gtr:valuePounds>90807</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:keyFindingsOutput><gtr:description>Foot-and-mouth disease (FMD) causes ongoing losses in Turkey and poses a threat to FMD free Europe. Control relies on mass vaccination of cattle every six months. Between September 2011 and July 2012, four retrospective outbreak investigations were performed in Turkey to assess FMD Asia-1 vaccine effectiveness (VE) in cattle, that is, vaccine efficacy assessed under field conditions. After adjustment for confounding, the new FMD Asia-1 TUR 11 vaccine had a VE against disease of 69% [95% CI: 50% to 81%]. There was no evidence that the old FMD Asia-1 Shamir vaccine provided adequate protection, with 69% of those vaccinated 2-5 times affected by clinical FMD. Efforts to achieve sustained herd immunity, through biannual vaccination of cattle are compromised by rapid population turnover and waning protection. Between autumn 2012 and spring 2013, a prospective field study was conducted, assessing immunity after routine vaccination. Four to five months after vaccination, only a third of single-vaccinated cattle had antibody levels above a threshold associated with protection. It was not until animals had received three vaccine doses in their lifetime that most maintained antibody levels above this threshold (64% to 86% depending on serotype). Many vaccinated animals will be unprotected for much of the year. Compared to a single-dose, a primary vaccination course of two-doses, given one month apart, greatly improved immunity. A dynamic model of the Turkish cattle population estimated that six months after the last round of vaccination almost half the cattle =24 months old remained unvaccinated. Only 50% of all cattle would have been vaccinated more than once in their life, with the last dose given =6 months ago. The FMD vaccination programme in Anatolian Turkey did not produce the high levels of immunity needed to control FMD without additional control measures.</gtr:description><gtr:exploitationPathways>We have developed approaches for assessing vaccine effectiveness for FMDV that could be applied to other livestock diseases.</gtr:exploitationPathways><gtr:id>CDD5B228-202A-4B57-8FFF-47258F883137</gtr:id><gtr:outcomeId>56d70656d89e91.16869364</gtr:outcomeId><gtr:sectors><gtr:sector>Agriculture, Food and Drink</gtr:sector></gtr:sectors></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>7EC344B3-F618-4354-BF0E-3BF927B32A63</gtr:id><gtr:title>Randomised field trial to evaluate serological response after foot-and-mouth disease vaccination in Turkey.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/11f3999c30506526773ef76982e02988"><gtr:id>11f3999c30506526773ef76982e02988</gtr:id><gtr:otherNames>Knight-Jones TJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>56d6ee47728be7.12662969</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0AA92290-0AB2-41D3-8700-34CD213C4881</gtr:id><gtr:title>Retrospective evaluation of foot-and-mouth disease vaccine effectiveness in Turkey.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/11f3999c30506526773ef76982e02988"><gtr:id>11f3999c30506526773ef76982e02988</gtr:id><gtr:otherNames>Knight-Jones TJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>545a4baec54f54.33101492</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>36BE4974-9BC8-49A7-B2C9-CD666C934442</gtr:id><gtr:title>Mass vaccination, immunity and coverage: modelling population protection against foot-and-mouth disease in Turkish cattle.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/11f3999c30506526773ef76982e02988"><gtr:id>11f3999c30506526773ef76982e02988</gtr:id><gtr:otherNames>Knight-Jones TJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>56d6ee47a8c658.16691839</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5B1B7485-B707-4DFA-AB25-41E3E85446BC</gtr:id><gtr:title>Veterinary and human vaccine evaluation methods.</gtr:title><gtr:parentPublicationTitle>Proceedings. Biological sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/11f3999c30506526773ef76982e02988"><gtr:id>11f3999c30506526773ef76982e02988</gtr:id><gtr:otherNames>Knight-Jones TJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0962-8452</gtr:issn><gtr:outcomeId>545a4bcfeac0e6.75339761</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">BBS/E/I/00001609</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>